breast cancer

News

Enhertu poised to move first line in HER2+ breast cancer

New data could make HER2-directed antibody-drug conjugate (ADC) Enhertu an option for previously untreated breast cancer for the first time.

News

Vials on a conveyor belt - pharma manufacturing

Trodelvy-Keytruda pairing hits the spot in breast cancer

Gilead Sciences has cemented the role of its TROP2 drug Trodelvy in triple-negative breast cancer with a study win in combination with MSD's Keytruda.

News

Pill that can slow breast cancer cleared for NHS use

AstraZeneca's oral drug Truqap will soon be available for people with advanced breast cancer via the NHS in England, as long as testing is available.

News

AZ, Daiichi get EU okay for breast cancer drug Datroway

AstraZeneca and Daiichi Sankyo have claimed approval from the European Commission for Datroway, their TROP2-directed ADC for breast cancer.

News

AZ grabs pair of EU approvals for top cancer drugs

AstraZeneca is celebrating two approvals for cancer drugs Imfinzi and Enhertu in the EU as it faces increased competition to its top-seller Tagrisso.

News

Pfizer's new drug data in breast cancer draws muted response

Pfizer and Arvinas' much-anticipated oral SERD vepdegestrant for breast cancer missed a key endpoint in its first phase 3 readout.

Enhertu poised to move first line in HER2+ breast cancer

Trodelvy-Keytruda pairing hits the spot in breast cancer

Pill that can slow breast cancer cleared for NHS use

AZ, Daiichi get EU okay for breast cancer drug Datroway

AZ grabs pair of EU approvals for top cancer drugs

Pfizer's new drug data in breast cancer draws muted response

Agios mulls early FDA filing for sickle cell therapy

Using AI-driven synthetic personas to take your insights fur...

breast cancer

Editor's Picks